Krystal Biotech (NASDAQ:KRYS) Given New $206.00 Price Target at Citigroup

Krystal Biotech (NASDAQ:KRYS) had its price objective lifted by Citigroup from $204.00 to $206.00 in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

KRYS has been the topic of several other reports. Evercore ISI lifted their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. Chardan Capital lifted their price target on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a report on Monday, August 5th. HC Wainwright reissued a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Tuesday. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Stifel Nicolaus boosted their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $197.00.

Krystal Biotech Stock Up 7.6 %

Shares of KRYS stock opened at $199.61 on Tuesday. The business has a 50 day moving average of $181.29 and a two-hundred day moving average of $180.58. The company has a market cap of $5.74 billion, a P/E ratio of 112.77 and a beta of 0.82. Krystal Biotech has a 52 week low of $93.95 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm’s revenue was up 879.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.67) EPS. Analysts expect that Krystal Biotech will post 2.96 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

A number of large investors have recently added to or reduced their stakes in the business. Jamison Private Wealth Management Inc. acquired a new position in shares of Krystal Biotech in the 2nd quarter valued at $28,000. GAMMA Investing LLC boosted its holdings in shares of Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after buying an additional 93 shares during the period. Key Financial Inc purchased a new position in shares of Krystal Biotech in the second quarter worth approximately $28,000. Blue Trust Inc. increased its position in shares of Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after acquiring an additional 163 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new stake in shares of Krystal Biotech during the third quarter valued at approximately $53,000. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).